40 patents
Utility
Polygenic Trait Prediction Using Local Ancestry
17 Aug 23
Provided herein are methods for determining polygenic traits and risks for medical use, such as cancer traits and risks, as well as treating diseases for which risk is identified and/or assessed.
Dmitry Pruss, Alexander Gutin, Elisha Hughes, Jerry Lanchbury
Filed: 16 Apr 21
Utility
Methods and Materials for Assessing Homologous Recombination Deficiency In Breast Cancer Subtypes
6 Jul 23
Provided herein are methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature.
Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 6 Dec 22
Utility
Methods and Materials for Assessing Homologous Recombination Deficiency
20 Apr 23
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature.
Victor Abkevich, Kirsten Timms, Alexander Gutin, Julia Reid
Filed: 14 Dec 22
Utility
Method of Using Biomarkers and Clinical Variables for Predicting Chemotherapy Benefit
13 Apr 23
Provided herein are methods for predicting chemotherapy benefit.
Alexander Gutin, Julia Reid, Ralf Kronenwett, Marsel Scheer
Filed: 14 Oct 22
Utility
Methods and Materials for Assessing Loss of Heterozygosity
13 Apr 23
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature.
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 14 Dec 22
Utility
Signatures for Predicting Cancer Immune Therapy Response
30 Mar 23
This disclosure generally relates to a molecular classification of cancer and particularly to molecular markers for predicting response to cancer therapy, including cancer immune therapy, and methods of use thereof.
Susanne WAGNER
Filed: 30 Nov 22
Utility
Method of using biomarkers and clinical variables for predicting chemotherapy benefit
22 Nov 22
Provided herein are methods for predicting chemotherapy benefit.
Alexander Gutin, Julia Reid, Ralf Kronenwett, Marsel Scheer
Filed: 4 Mar 20
Utility
Gene Signatures for Cancer Prognosis
18 Aug 22
Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
Steven Stone, Alexander Gutin, Susanne Wagner, Julia E. Reid
Filed: 23 Feb 22
Utility
Methods of Detecting Cancer
4 Aug 22
Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided.
Alexander Gutin, Jerry Lanchbury, Susanne Wagner, Victor Abkevich
Filed: 13 Jan 22
Utility
Methods and Materials for Assessing Allelic Imbalance
30 Jun 22
Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.
Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 8 Dec 21
Utility
Detecting Cancer Risk
30 Jun 22
The present disclosure relates to methods, kits, and systems for assessing the risk of a human subject for developing a cancer, including genetic risk assessment, clinical risk assessment, and combinations of both to improve risk analysis.
Elisha Hughes, Alexander Gutin
Filed: 4 Oct 21
Utility
Methods and Materials for Assessing Loss of Heterozygosity
30 Jun 22
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature.
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 12 Oct 21
Utility
Gene Signatures for Cancer Prognosis
14 Apr 22
Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
Steven Stone, Alexander Gutin, Julia Reid
Filed: 24 Sep 21
Utility
Copy number variant caller
25 Jan 22
Direct targeted sequencing (DTS) methods and a hidden Markov model (HMM) can be used to call the copy number of a segment of interest within a region of interest.
Kevin R. Haas, Xin Wang, Peter V. Grauman
Filed: 23 Mar 18
Utility
Methods and materials for assessing allelic imbalance
18 Jan 22
Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.
Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 11 Mar 20
Utility
Gene signatures for cancer prognosis
16 Nov 21
Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
Steven Stone, Alexander Gutin, Julia Reid
Filed: 11 Nov 16
Utility
Method of treating cancer
16 Nov 21
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature.
Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
Filed: 21 Nov 19
Utility
Hereditary Cancer Genes
11 Nov 21
The invention generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof.
Kirsten Timms, Brian Allen, Anne-Renee Hartman
Filed: 22 Jul 21
Utility
Methods and Materials for Assessing Homologous Recombination Deficiency
7 Oct 21
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature.
Victor Abkevich, Kirsten Timms, Alexander Gutin
Filed: 21 Jun 21
Utility
Hereditary cancer genes
31 Aug 21
The invention generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof.
Kirsten Timms, Brian Allen, Anne-Renee Hartman
Filed: 5 Dec 14